hotspot -WSS

hotspot

author：leisure time 2025-09-30 22:27:48 - browse：8

An army of wooden figures under blue and pink lighting — biotech coverage from STAT — Adobe

In an abrupt change of course from plans earlier in the month, at-home test maker Cue Health is laying off all of its employees and shutting down as of Friday, May 24.

The company, which grew to prominence during the Covid-19 pandemic as the maker of one of the only molecular at-home tests for the virus, has been teetering on the edge of insolvency for months. The shutdown, first reported by the San Diego Union-Tribune, comes just over a week after the FDA warned consumers not to use Cue’s only FDA-authorized product, a Covid-19 test kit.

Cue had previously notified 49% of its workers on May 1 that they would be laid off from the company, effective July 1. But in a WARN notice filed with California state regulators on May 20, chief human resources officer Allison Blackwell said that due to the “fluid nature of this situation,” all U.S. employees who had not already received notice of termination would be receiving one. All employees will receive their last paychecks on May 24, the notice said.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： Cigna wins case to block Amy Bricker's move to CVS

focus

WSS

My daughter's legacy lives on through her writing, phage therapy

Faced with fears of OxyContin misuse, sales reps touted its safety

Curing rare childhood diseases will falter unless Congress steps up

ALS patient reclaims some autonomy thanks to wearable 'robot'

NIH tests clinical research in primary care with $30 million program

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

explore

hotspot

This article is exclusive to STAT+ subscribers

Unlock this article — and get additional analysis of the technologies disrupting health care — by subscribing to STAT+.

knowledge

The high cost of giving birth even with insurance

Pharma budget tightening trickles down to Doximity

Wildfire smoke exposes gaps in outdoor worker protections

Kim Kardashian sparks debate on benefits of full

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Some of the ways extreme heat will change life as we know it

Moonlake's readout produced a cash windfall. Risks remain

How the BIOSECURE Act is already affecting U.S., Chinese life science firms

Medical leaders decry Supreme Court decision on affirmative action

Readers discuss the intersection of pregnancy and addiction

focus

TB outbreak tied to bone grafts underscores testing shortcomings

'Disease catastrophe' looms in Sudan as health conditions deteriorate, medics warn

White House drug shortages task force keeps mum with Congress

TB outbreak tied to bone grafts underscores testing shortcomings

Timeline: Special counsel's investigation into Trump's handling of classified documents

Listen: Your guide to Wegovy's blockbuster heart study

hotspot

entertainment

focus

hotspot